The pharmacokinetic profile of plasma-derived mannan-binding lectin in healthy adult volunteers and patients with Staphylococcus aureus septicaemia

Scandinavian Journal of Infectious Diseases

Volumn 40, Issue 1, 2008, Pages 44-48

  Bang, Peter ^a   Laursen, Inga ^a   Thornberg, Klaus ^b   Schierbeck, Jens ^c   Nielsen, Bjarne ^d   Valdimarsson, Helgi ^e   Koch, Claus ^f   Christiansen, Michael ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d Cyncron   (Denmark)

^e LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; MANNAN BINDING LECTIN; STEROID;

ADULT; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; CLINICAL TRIAL; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PROTEIN BLOOD LEVEL; SEPTICEMIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; MALE; MANNOSE-BINDING LECTIN; MIDDLE AGED; SEPSIS; STAPHYLOCOCCAL INFECTIONS;

EID: 37749020355     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540701522959     Document Type: Article

References (17)

1. Dommett, RM, Klein, N. and Turner, MW. (2006) Mannose-binding lectin in innate immunity: Past, present and future. Tissue Antigens, 68, pp. 193-209.
2. Fraser, DA, Bohlson, SS, Jasinskiene, N., Rawal, N., Palmarini, G. and Ruis, S. (2006) C1q and MBL, components of the innate immune system, influence monocyte cytokine expression. J Leukoc Biol, 80, pp. 107-116.
3. Madsen, HO, Garred, P., Thiel, S., Kurtzhals, JA, Lamm, LU and Ryder, LP (1995) Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol, 155, pp. 3013-3020.
4. Steffensen, R., Thiel, S., Varming, K., Jersild, C. and Jensenius, JC. (2000) Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. J Immunol Methods, 241, pp. 33-42.
5. Kilpatrick, DC. (2002) Mannan-binding lectin: Clinical significance and applications. Biochim Biophys Acta, 1572, pp. 401-413.
6. Saevarsdottir, S., Kristjansdottir, H., Grondal, G., Vikingsdottir, T., Gudnason, V. and Valdimarsson, H. (2006) Mannan-binding lectin and complement C4A in Icelandic multicase families with systemic lupus erythematosus. Ann Rheum Dis, 65, pp. 1462-1467.
7. Tran, CT, Kjeldsen, K., Haunsø, S., Hoiby, N., Johansen, HK and Christiansen, M. (2007) Mannan- binding lectin is a determinant of survival in infective endocarditis. Clin Exp Immunol, 148, pp. 101-105.
8. Eisen, DP, Dean, MM, Thomas, P., Marshall, P., Gerns, N. and Heatley, S. (2006) Low mannose-binding lectin function is associated with sepsis in adult patients. FEMS Immunol Med Microbiol, 48, pp. 274-282.
9. Fevang, B., Mollness, TE, Holm, AM, Ueland, T., Heggelund, L. and Damas, JK (2005) Common variable immunodeficiency and the complement system: low mannose-binding lectin levels are associated with bronchiectasis. Clin Exp Immunol, 142, pp. 576-584.
10. Valdimarsson, H., Vikingsdottir, T., Bang, P., Saevarsdottir, S., Godjonsson, JE and Oskarsson, O. (2004) Human plasma-derived mannose-binding lectin: A phase I safety and pharmacokinetic study. Scand J Immunol, 59, pp. 97-102.
11. Laursen, I. (2003) Mannan-binding lectin (MBL) production from human plasma. Biochem Soc Trans, 31, pp. 758-762.
12. Garred, P., Pressler, T., Lanng, S., Madsen, HO, Moser, C. and Laursen, I. (2002) Mannose-binding lectin (MBL) therapy in an MBL-deficient patient with severe cystic fibrosis lung disease. Pediatr Pulmonol, 33, pp. 201-207.
13. Shargel, L. and Yu, ABC (2004) Applied Biopharmaceutics & Pharmacokinetics, The McGraw-Hill Companies Inc, New York
14. Bergmann, J., Christiansen, M., Laursen, I., Bang, P., Hansen, NE and Ellegaard, J. (2003) Low levels of mannose-binding lectin do not affect occurrence of severe infections or duration of fever in acute myeloid leukaemia during remission induction therapy. Eur J Haematol, 70, pp. 91-97.
15. Petersen, KA, Matthiesen, F., Agger, T., Kongerslev, L., Thiel, S. and Cornelissen, K. (2006) Phase I safety, tolerability, and pharmacokinetic study of recombinant human mannan-binding lectin. J Clin Immunol, 26, pp. 465-475.
16. Ilias, W., List, W., Decruyenaere, J., Lignian, H., Knaub, S. and Schindel, F. (2000) Antithrombin III in patients with severe sepsis: A pharmacokinetic study. Intensive Care Med, 26, pp. 704-715.
17. Jensen, PH, Weilguny, D., Matthiesen, F., McGuire, KA, Shi, L. and Hojrup, P. (2005) Characterization of the oligomer structure of recombinant human mannan-binding lectin. J Biol Chem, 280, pp. 11043-11051.